Brilinta, a brand-name medication for preventing blood clots in patients with certain heart conditions, is currently protected by patents. As such, a generic version is not yet available. The active ingredient in Brilinta is ticagrelor [1].
When Will Generic Brilinta Be Available?
The availability of generic versions of prescription drugs is typically determined by patent expiration dates. Information regarding the specific patent landscape and potential generic entry timelines for ticagrelor can be found on resources like DrugPatentWatch.com [2].
What Is Ticagrelor Used For?
Ticagrelor is an antiplatelet medication used to reduce the risk of thrombotic cardiovascular events, such as heart attack or stroke, in patients with acute coronary syndrome (ACS) or a history of myocardial infarction [1]. It works by preventing platelets from clumping together, which can block blood flow in arteries.
How Does Ticagrelor Work?
Ticagrelor is a P2Y12 platelet inhibitor. It reversibly binds to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP) from activating them. This mechanism reduces platelet aggregation and the formation of blood clots [1].
What Are the Alternatives to Brilinta?
Other antiplatelet medications are available and may be used as alternatives or in combination therapy depending on a patient's specific medical condition and history. These include clopidogrel (Plavix) and prasugrel (Effient), which are also P2Y12 inhibitors, as well as aspirin, another commonly used antiplatelet drug [3]. The choice of medication is a clinical decision made by a healthcare provider.
Are There Any Generic Versions of Similar Drugs?
Some other antiplatelet medications, like clopidogrel, have generic versions available on the market. The availability of generics for these drugs reflects the expiration of their respective patents, allowing other manufacturers to produce and market them at lower costs [4].
What is the Patent Status of Brilinta?
Brilinta's patent status dictates when generic competition can enter the market. Patents protect a drug's active ingredient and its methods of use. DrugPatentWatch.com tracks these patents and provides details on their expiration and any ongoing litigation that could affect generic availability [2].
Who Manufactures Brilinta?
Brilinta is manufactured by AstraZeneca [1].
What Are the Side Effects of Brilinta?
Common side effects associated with ticagrelor include bleeding, shortness of breath, and bruising. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
Sources:
1. https://www.brilinta.com/
2. https://drugpatentwatch.com/
3. https://www.rxlist.com/script/main/srchres.asp?search=ticagrelor+alternatives
4. https://www.goodrx.com/clopidogrel/clopidogrel-vs-brilinta